Merck plans to move manufacturing of its biggest drug, Keytruda, to a new US factory and lab in Delaware
Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future drugs to market.
Keytruda is currently made in Ireland and by contract manufacturers in the United States. President Donald Trump has complained about Ireland acting as a low-cost drug factory center and tax haven at the expense of U.S. workers and tax collections.
The new Merck complex in Wilmington will be a 'cornerstone of our biotech future,' chief executive Robert W. Davis said at a groundbreaking Tuesday on the former DuPont Co. chemical and office campus. It will be 'the future U.S. home for producing Keytruda for U.S. patients.'
Though manufacturing will be automated with robotics and artificial intelligence software, Davis said Merck would create 500 new jobs in advanced manufacturing and research and development at the site by the time construction is complete in five years and potentially thousands more drug development jobs long-term.
'This is a significantly new era in drug development,' said Sanat Chattopadhyay, president of the company's manufacturing division. Producing bio-based and complex therapies in the United States for the U.S. market 'means we will be able to speed access to patients much faster.'
Merck officials said the site was chosen over rival locations in Pennsylvania, Maryland, North Carolina, Massachusetts, and other states where Merck has facilities. Delaware officials earlier this year approved grants of up to $30 million for the project to help attract Merck.
The company is among the larger employers in the Philadelphia area, with around 14,700 staff spread across its Upper Gwynedd Township offices, West Point manufacturing plants, and Spring House research labs, all in Montgomery County, and other area sites.
Merck plans to complete labs at the former DuPont Co. Chestnut Run research and production site at 984 Centre Rd. in Wilmington by 2028 and add manufacturing and offices by 2030.
Delaware's gain isn't Pennsylvania's loss, said Mike Wojewodka, president of developer MRA Group, which has also built biotech centers at former industrial sites in Philadelphia and Montgomery County. He said both states are among those competing for biotech facilities, and both benefit from large regional employers expanding, no matter where the facilities are.
Speaking at the groundbreaking, both Gov. Matt Meyer and New Castle County Executive Marcus Henry smilingly urged employees from Merck's Rahway, N.J., headquarters to move their homes to Delaware, which has fewer layers of municipal government and strong state funding for public schools that keep property taxes lower than in the Garden State.
Merck will deploy robots, artificial intelligence software, and other new technologies at the Wilmington location.
Among its goals: to develop subcutaneous drug delivery (injection directly into fatty tissue below the skin) for Keytruda, produce antibody-drug conjugates that combine biological disease-fighting cells with chemotherapy drugs, and streamline production to speed new products to patients faster than older plants, Chattopadhyay said.
MRA, with initial funding from Fulton Bank, bought the former DuPont complex for $40 million in 2021 as DuPont CEO Edward Breen sold and spun off a series of business units. At its peak in the 1970s, DuPont and its chemical and materials businesses employed more than 30,000 Delaware residents and dominated the state economically. It currently employs around 2,500.
The developer has leveled old buildings and is overseeing pollution remediation at the site.
The new Merck factory is under construction alongside a rising Marriott Residence Inn, and a childcare center for workers' families, among other amenities.
Other tenants at the complex include DuPont, chemical maker Celanese, which operates a former DuPont business, and Delaware-based biotech companies Solenis and Prelude. Prelude is a spinoff of another Delaware-based biotech company, publicly traded, Wilmington-based Incyte, the largest drug company founded in the Philadelphia area since the 1990s.
The new plant is underway at a time when Philadelphia area biotech and bio manufacturing development has slumped following an investment boom in the late 2010s.
MRA's other biotech projects include sites in Spring House, near Merck's labs; University City near the University of Pennsylvania and Veterans' Administration hospitals; and at Pennovation, Penn's engineering and business center at the former DuPont paint factory in South Philadelphia.
Merck in March told workers that it plans to close one of its smaller Pennsylvania facilities this summer — the Cherokee plant in Northumberland County, idling 163 workers.
___
© 2025 The Philadelphia Inquirer, LLC.
Distributed by Tribune Content Agency, LLC.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Trump Says China ‘Not Easy' as Trade Talks Resume
Good morning. Trade talks between the US and China continue into a second day in London. The Trump administration mobilizes Marines in response to the LA protests. And the Ritz London claims the top spot in the UK National Restaurant Awards. Listen to the day's top stories. Trade talks between the US and China will continue into a second day as the two sides look to ease tensions over shipments of technology and rare earth elements. 'We are doing well with China,' Donald Trump told reporters at the White House, adding ' China's not easy.'
Business of Fashion
an hour ago
- Business of Fashion
The Independents Acquires Culinary Studio We Are Ona
Fashion communications conglomerate The Independents has acquired culinary studio We Are Ona. Founded in Paris in 2019 by chef and Noma alumnus Luca Pronzato, We Are Ona produces immersive dinners, including for Chanel, Balenciaga, Coperni, Alaïa and Saint Laurent. After working together on various projects for clients over the past few years, joining forces felt inevitable, said Independents co-founder and chief executive Isabelle Chouvet. 'We started to collaborate a lot and then it was natural that we had to officialise this union,' said Chouvet. '[Pronzato] is the only one doing what he's doing. He is able to push the boundaries of innovation, he is the only one who has the network of talents. He has the vision and understands the client's needs.' We Are Ona collaborates with artists like Willo Perron, who has staged shows for Beyoncé and Drake; Carsten Höller, known for his interactive installations; and Michelin-starred chefs including Dalad Kambhu and Mory Sacko. Beyond producing events for brands, the firm hosts pop-ups open to the public, most recently a restaurant experience featuring a dramatic, 100-feet-long sculptural lighting installation in New York's WSA Building with fashion show producer Alexandre de Betak (whose Bureau Betak was acquired by The Independents in 2021) in May. The set of a We Are Ona-produced dinner for Balenciaga. (Courtesy) Being under The Independents' umbrella will help We Are Ona continue expansion in the US (where it opened an office earlier this year), the Middle East and Asia, said Pronzato. This marks The Independents' first acquisition in the culinary space; it comes as foodie culture reaches a new zenith, and as food becomes an increasingly important tool fashion brands use to engage their customers. When it comes to food, fashion brands are raising the stakes — looking for high-production events that double as marketing moments: 'It's not only dinner to have a dinner, it's dinner to create a brand moment,' said Pronzato. 'These experiences can create an emotional link. When you sit at the table, the experience is different than when you buy a bag.' The acquisition is The Independents' third this year, and part of an ongoing spree that began in 2023 when it set its sights on doubling in size. In April, The Independents bought design studio 2x4 and in May, Paris-based documentary production company Terminal 9 Studios. Now, the company has over 20 agencies in its ranks and counts over 1,200 employees in offices across cities including Barcelona, Beijing, London, Los Angeles, Milan, New York, Seoul, Shanghai and Paris. Group revenue totalled $800 million in 2024, according to the company. Learn more: Why Food Is Everywhere in Fashion Advertising As foodie culture peaks and the cost of living rises, food is popping up more than ever in fashion imagery.
Yahoo
2 hours ago
- Yahoo
US business group says Washington should treat Taiwan like partner not adversary
TAIPEI (Reuters) -The United States should treat Taiwan like a partner and not an adversary, remove new and proposed tariffs, restore high-level cabinet visits and agree a double taxation deal, the American Chamber of Commerce in Taiwan said on Tuesday. Taiwan, which China views as its own territory, enjoyed strong support from U.S. President Donald Trump's first administration, which regularized arms sales that President Joe Biden continued. But Trump, as part of his sweeping tariffs on countries around the world, in April said he would put a 32% tariff on Taiwan, before pausing them for 90 days. Taiwan and the United States are still in talks to resolve the issue. AmCham Taiwan President Carl Wegner, releasing the group's 2025 White Paper, said he would be leading a delegation to Washington later this month to have "door knock" talks with officials on concerns about the tariffs and how to boost Taiwan-U.S. business ties. "Taiwan is a reliable friend of the United States, an essential democratic partner in the Indo Pacific, a major investor in American industry and a critical contributor to supply chain resilience," he told reporters in Taipei. Trade measures that were initially designed to address unfair practices by strategic competitors like China are now being targeted at friends like Taiwan, Wegner said. "It is in America's interests to ensure Taiwan is treated like a partner, not like an adversary." The White Paper said an agreement to avoid double taxation, currently stalled in the U.S. Senate, should urgently be resolved to remove investment barriers, while high-level visits by U.S. cabinet members should resume. Neither Taiwan nor the United States have provided substantive public updates on the tariff talks. The U.S. Department of Commerce did not respond to requests for comment sent outside of Washington office hours.
